Which has higher valuation & earnings, VOR or FULC?

Vor Biopharma has higher earnings, but lower revenue than Fulcrum Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Vor Biopharma N/A N/A N/A N/A N/A Fulcrum Therapeutics $80M 3.52 -$74.88M -$1.21 N/A

Is VOR or FULC more profitable?

Vor Biopharma's return on equity of 0.00% beat Fulcrum Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Vor Biopharma N/A N/A N/A Fulcrum Therapeutics N/A -25.38% -24.15%

Does the media prefer VOR or FULC?

In the previous week, Vor Biopharma had 5 more articles in the media than Fulcrum Therapeutics. MarketBeat recorded 7 mentions for Vor Biopharma and 2 mentions for Fulcrum Therapeutics. Fulcrum Therapeutics' average media sentiment score of 0.28 beat Vor Biopharma's score of 0.21 indicating that Fulcrum Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vor Biopharma 1 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Fulcrum Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is FULC or ODTX more profitable?

Odyssey Therapeutics' return on equity of 0.00% beat Fulcrum Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Fulcrum Therapeutics N/A -25.38% -24.15% Odyssey Therapeutics N/A N/A N/A

Does the media prefer FULC or ODTX?

In the previous week, Fulcrum Therapeutics had 1 more articles in the media than Odyssey Therapeutics. MarketBeat recorded 2 mentions for Fulcrum Therapeutics and 1 mentions for Odyssey Therapeutics. Odyssey Therapeutics' average media sentiment score of 1.79 beat Fulcrum Therapeutics' score of 0.28 indicating that Odyssey Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fulcrum Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Odyssey Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media refer more to MNKD or FULC?

In the previous week, MannKind had 6 more articles in the media than Fulcrum Therapeutics. MarketBeat recorded 8 mentions for MannKind and 2 mentions for Fulcrum Therapeutics. MannKind's average media sentiment score of 0.41 beat Fulcrum Therapeutics' score of 0.28 indicating that MannKind is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MannKind 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Fulcrum Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to MGTX or FULC?

In the previous week, MeiraGTx had 3 more articles in the media than Fulcrum Therapeutics. MarketBeat recorded 5 mentions for MeiraGTx and 2 mentions for Fulcrum Therapeutics. MeiraGTx's average media sentiment score of 0.40 beat Fulcrum Therapeutics' score of 0.28 indicating that MeiraGTx is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MeiraGTx 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Fulcrum Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is AKTS or FULC more profitable?

Aktis Oncology's return on equity of 0.00% beat Fulcrum Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Aktis Oncology N/A N/A N/A Fulcrum Therapeutics N/A -25.38% -24.15%

Does the media prefer AKTS or FULC?

In the previous week, Aktis Oncology had 4 more articles in the media than Fulcrum Therapeutics. MarketBeat recorded 6 mentions for Aktis Oncology and 2 mentions for Fulcrum Therapeutics. Fulcrum Therapeutics' average media sentiment score of 0.28 beat Aktis Oncology's score of 0.15 indicating that Fulcrum Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aktis Oncology 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Fulcrum Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Fulcrum Therapeutics (FULC) Competitors

$3.69 +0.01 (+0.27%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$3.70 +0.00 (+0.14%)

As of 10/2/2026 07:30 PM Eastern

Compare

FULC vs. VOR, ODTX, MNKD, MGTX, and AKTS

Should you buy Fulcrum Therapeutics stock or one of its competitors? Fulcrum Therapeutics's main competitors and comparable companies include Vor Biopharma (VOR), Odyssey Therapeutics (ODTX), MannKind (MNKD), MeiraGTx (MGTX), and Aktis Oncology (AKTS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Fulcrum Therapeutics compare to Vor Biopharma?

Vor Biopharma (NASDAQ:VOR) and Fulcrum Therapeutics (NASDAQ:FULC) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, dividends, risk, institutional ownership, profitability and valuation.

Vor Biopharma presently has a consensus price target of $41.71, indicating a potential upside of 123.19%. Fulcrum Therapeutics has a consensus price target of $8.20, indicating a potential upside of 122.22%. Given Vor Biopharma's stronger consensus rating and higher probable upside, equities research analysts plainly believe Vor Biopharma is more favorable than Fulcrum Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vor Biopharma	0 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.90
Fulcrum Therapeutics	4 Sell rating(s)	7 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75

97.3% of Vor Biopharma shares are owned by institutional investors. Comparatively, 89.8% of Fulcrum Therapeutics shares are owned by institutional investors. 0.3% of Vor Biopharma shares are owned by insiders. Comparatively, 7.3% of Fulcrum Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Vor Biopharma has a beta of 1.78, indicating that its stock price is 78% more volatile than the broader market. Comparatively, Fulcrum Therapeutics has a beta of 2.63, indicating that its stock price is 163% more volatile than the broader market.

Vor Biopharma has higher earnings, but lower revenue than Fulcrum Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vor Biopharma	N/A	N/A	N/A	N/A	N/A
Fulcrum Therapeutics	$80M	3.52	-$74.88M	-$1.21	N/A

Vor Biopharma's return on equity of 0.00% beat Fulcrum Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vor Biopharma	N/A	N/A	N/A
Fulcrum Therapeutics	N/A	-25.38%	-24.15%

In the previous week, Vor Biopharma had 5 more articles in the media than Fulcrum Therapeutics. MarketBeat recorded 7 mentions for Vor Biopharma and 2 mentions for Fulcrum Therapeutics. Fulcrum Therapeutics' average media sentiment score of 0.28 beat Vor Biopharma's score of 0.21 indicating that Fulcrum Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vor Biopharma	1 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Fulcrum Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Vor Biopharma beats Fulcrum Therapeutics on 8 of the 12 factors compared between the two stocks.

How does Fulcrum Therapeutics compare to Odyssey Therapeutics?

Fulcrum Therapeutics (NASDAQ:FULC) and Odyssey Therapeutics (NASDAQ:ODTX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, dividends, earnings, analyst recommendations, profitability, media sentiment, institutional ownership and risk.

Fulcrum Therapeutics presently has a consensus target price of $8.20, suggesting a potential upside of 122.22%. Odyssey Therapeutics has a consensus target price of $35.75, suggesting a potential upside of 72.46%. Given Fulcrum Therapeutics' higher possible upside, analysts clearly believe Fulcrum Therapeutics is more favorable than Odyssey Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fulcrum Therapeutics	4 Sell rating(s)	7 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75
Odyssey Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

89.8% of Fulcrum Therapeutics shares are held by institutional investors. 7.3% of Fulcrum Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Odyssey Therapeutics' return on equity of 0.00% beat Fulcrum Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fulcrum Therapeutics	N/A	-25.38%	-24.15%
Odyssey Therapeutics	N/A	N/A	N/A

In the previous week, Fulcrum Therapeutics had 1 more articles in the media than Odyssey Therapeutics. MarketBeat recorded 2 mentions for Fulcrum Therapeutics and 1 mentions for Odyssey Therapeutics. Odyssey Therapeutics' average media sentiment score of 1.79 beat Fulcrum Therapeutics' score of 0.28 indicating that Odyssey Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Fulcrum Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Odyssey Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Odyssey Therapeutics has lower revenue, but higher earnings than Fulcrum Therapeutics. Odyssey Therapeutics is trading at a lower price-to-earnings ratio than Fulcrum Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fulcrum Therapeutics	$80M	3.52	-$74.88M	-$1.21	N/A
Odyssey Therapeutics	N/A	N/A	N/A	-$6.77	N/A

Summary

Fulcrum Therapeutics beats Odyssey Therapeutics on 7 of the 12 factors compared between the two stocks.

How does Fulcrum Therapeutics compare to MannKind?

MannKind (NASDAQ:MNKD) and Fulcrum Therapeutics (NASDAQ:FULC) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, profitability, analyst recommendations, institutional ownership, earnings, valuation and dividends.

In the previous week, MannKind had 6 more articles in the media than Fulcrum Therapeutics. MarketBeat recorded 8 mentions for MannKind and 2 mentions for Fulcrum Therapeutics. MannKind's average media sentiment score of 0.41 beat Fulcrum Therapeutics' score of 0.28 indicating that MannKind is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MannKind	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Fulcrum Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Fulcrum Therapeutics has a net margin of 0.00% compared to MannKind's net margin of -11.08%. MannKind's return on equity of 0.00% beat Fulcrum Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MannKind	-11.08%	N/A	-6.31%
Fulcrum Therapeutics	N/A	-25.38%	-24.15%

MannKind has a beta of 1.09, indicating that its stock price is 9% more volatile than the broader market. Comparatively, Fulcrum Therapeutics has a beta of 2.63, indicating that its stock price is 163% more volatile than the broader market.

49.6% of MannKind shares are owned by institutional investors. Comparatively, 89.8% of Fulcrum Therapeutics shares are owned by institutional investors. 2.6% of MannKind shares are owned by company insiders. Comparatively, 7.3% of Fulcrum Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

MannKind has higher revenue and earnings than Fulcrum Therapeutics. MannKind is trading at a lower price-to-earnings ratio than Fulcrum Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MannKind	$348.97M	3.50	$5.86M	-$0.13	N/A
Fulcrum Therapeutics	$80M	3.52	-$74.88M	-$1.21	N/A

MannKind currently has a consensus target price of $8.34, suggesting a potential upside of 119.57%. Fulcrum Therapeutics has a consensus target price of $8.20, suggesting a potential upside of 122.22%. Given Fulcrum Therapeutics' higher possible upside, analysts clearly believe Fulcrum Therapeutics is more favorable than MannKind.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MannKind	2 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50
Fulcrum Therapeutics	4 Sell rating(s)	7 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75

Summary

MannKind beats Fulcrum Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Fulcrum Therapeutics compare to MeiraGTx?

MeiraGTx (NASDAQ:MGTX) and Fulcrum Therapeutics (NASDAQ:FULC) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, profitability, risk, earnings, dividends and media sentiment.

MeiraGTx has a net margin of 19.87% compared to Fulcrum Therapeutics' net margin of 0.00%. MeiraGTx's return on equity of 283.85% beat Fulcrum Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MeiraGTx	19.87%	283.85%	29.39%
Fulcrum Therapeutics	N/A	-25.38%	-24.15%

67.5% of MeiraGTx shares are owned by institutional investors. Comparatively, 89.8% of Fulcrum Therapeutics shares are owned by institutional investors. 7.4% of MeiraGTx shares are owned by insiders. Comparatively, 7.3% of Fulcrum Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

MeiraGTx has a beta of 1.35, indicating that its stock price is 35% more volatile than the broader market. Comparatively, Fulcrum Therapeutics has a beta of 2.63, indicating that its stock price is 163% more volatile than the broader market.

MeiraGTx currently has a consensus target price of $24.71, indicating a potential upside of 129.05%. Fulcrum Therapeutics has a consensus target price of $8.20, indicating a potential upside of 122.22%. Given MeiraGTx's stronger consensus rating and higher possible upside, analysts plainly believe MeiraGTx is more favorable than Fulcrum Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MeiraGTx	0 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.78
Fulcrum Therapeutics	4 Sell rating(s)	7 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75

Fulcrum Therapeutics has lower revenue, but higher earnings than MeiraGTx. Fulcrum Therapeutics is trading at a lower price-to-earnings ratio than MeiraGTx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MeiraGTx	$81.39M	12.73	-$114.20M	$0.71	15.20
Fulcrum Therapeutics	$80M	3.52	-$74.88M	-$1.21	N/A

In the previous week, MeiraGTx had 3 more articles in the media than Fulcrum Therapeutics. MarketBeat recorded 5 mentions for MeiraGTx and 2 mentions for Fulcrum Therapeutics. MeiraGTx's average media sentiment score of 0.40 beat Fulcrum Therapeutics' score of 0.28 indicating that MeiraGTx is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MeiraGTx	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Fulcrum Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

MeiraGTx beats Fulcrum Therapeutics on 14 of the 17 factors compared between the two stocks.

How does Fulcrum Therapeutics compare to Aktis Oncology?

Aktis Oncology (NASDAQ:AKTS) and Fulcrum Therapeutics (NASDAQ:FULC) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and media sentiment.

28.8% of Aktis Oncology shares are owned by institutional investors. Comparatively, 89.8% of Fulcrum Therapeutics shares are owned by institutional investors. 3.3% of Aktis Oncology shares are owned by insiders. Comparatively, 7.3% of Fulcrum Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Aktis Oncology had 4 more articles in the media than Fulcrum Therapeutics. MarketBeat recorded 6 mentions for Aktis Oncology and 2 mentions for Fulcrum Therapeutics. Fulcrum Therapeutics' average media sentiment score of 0.28 beat Aktis Oncology's score of 0.15 indicating that Fulcrum Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aktis Oncology	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Fulcrum Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Aktis Oncology currently has a consensus target price of $35.63, suggesting a potential upside of 92.36%. Fulcrum Therapeutics has a consensus target price of $8.20, suggesting a potential upside of 122.22%. Given Fulcrum Therapeutics' higher possible upside, analysts plainly believe Fulcrum Therapeutics is more favorable than Aktis Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aktis Oncology	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.91
Fulcrum Therapeutics	4 Sell rating(s)	7 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75

Aktis Oncology's return on equity of 0.00% beat Fulcrum Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aktis Oncology	N/A	N/A	N/A
Fulcrum Therapeutics	N/A	-25.38%	-24.15%

Aktis Oncology has higher earnings, but lower revenue than Fulcrum Therapeutics. Aktis Oncology is trading at a lower price-to-earnings ratio than Fulcrum Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aktis Oncology	$6.50M	153.15	-$63.73M	-$0.82	N/A
Fulcrum Therapeutics	$80M	3.52	-$74.88M	-$1.21	N/A

Summary

Aktis Oncology beats Fulcrum Therapeutics on 9 of the 15 factors compared between the two stocks.

Get Fulcrum Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FULC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

FULC vs. The Competition

Export

Metric	Fulcrum Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$281.54M	$3.85B	$7.15B	$13.28B
Dividend Yield	N/A	3.65%	2.54%	17.33%
P/E Ratio	-3.05	13.00	274.71	26.04
Price / Sales	3.52	1,288.64	656.46	105.13
Price / Cash	N/A	123.39	78.87	52.62
Price / Book	0.57	16.57	10.93	6.31
Net Income	-$74.88M	-$22.66M	$3.51B	$362.16M
7 Day Performance	-1.34%	-2.97%	-2.00%	-1.66%
1 Month Performance	-4.16%	-10.82%	-6.19%	-4.68%
1 Year Performance	-59.98%	19.00%	8.03%	1.57%

Fulcrum Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
FULC Fulcrum Therapeutics	1.7663 of 5 stars	$3.69 +0.3%	$8.20 +122.2%	-60.0%	$281.54M	$80M	N/A	55
VOR Vor Biopharma	1.902 of 5 stars	$18.33 +0.1%	$41.71 +127.6%	-50.1%	$1.08B	N/A	N/A	76
ODTX Odyssey Therapeutics	3.2213 of 5 stars	$22.44 +4.5%	$35.75 +59.3%	N/A	$1.08B	N/A	N/A	100	Positive News
MNKD MannKind	2.3468 of 5 stars	$3.34 -0.3%	$8.34 +149.8%	-34.0%	$1.07B	$348.97M	N/A	592
MGTX MeiraGTx	3.8261 of 5 stars	$11.13 +0.2%	$24.71 +122.1%	+27.7%	$1.07B	$81.39M	15.68	393	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:FULC) was last updated on 10/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Fulcrum Therapeutics (FULC) Competitors

FULC vs. VOR, ODTX, MNKD, MGTX, and AKTS

How does Fulcrum Therapeutics compare to Vor Biopharma?

Summary

How does Fulcrum Therapeutics compare to Odyssey Therapeutics?

Summary

How does Fulcrum Therapeutics compare to MannKind?

Summary

How does Fulcrum Therapeutics compare to MeiraGTx?

Summary

How does Fulcrum Therapeutics compare to Aktis Oncology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FULC vs. The Competition

Fulcrum Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Fulcrum Therapeutics (FULC) Competitors

FULC vs. VOR, ODTX, MNKD, MGTX, and AKTS

How does Fulcrum Therapeutics compare to Vor Biopharma?

Do analysts rate VOR or FULC?

Do insiders & institutionals believe in VOR or FULC?

Which has more risk & volatility, VOR or FULC?

Which has higher valuation & earnings, VOR or FULC?

Is VOR or FULC more profitable?

Does the media prefer VOR or FULC?

Summary

How does Fulcrum Therapeutics compare to Odyssey Therapeutics?

Do analysts recommend FULC or ODTX?

Do insiders & institutionals hold more shares of FULC or ODTX?

Is FULC or ODTX more profitable?

Does the media prefer FULC or ODTX?

Which has stronger earnings and valuation, FULC or ODTX?

Summary

How does Fulcrum Therapeutics compare to MannKind?

Does the media refer more to MNKD or FULC?

Is MNKD or FULC more profitable?

Which has more risk & volatility, MNKD or FULC?

Do institutionals & insiders hold more shares of MNKD or FULC?

Which has preferable valuation and earnings, MNKD or FULC?

Do analysts prefer MNKD or FULC?

Summary

How does Fulcrum Therapeutics compare to MeiraGTx?

Is MGTX or FULC more profitable?

Do institutionals & insiders have more ownership in MGTX or FULC?

Which has more volatility and risk, MGTX or FULC?

Do analysts rate MGTX or FULC?

Which has higher earnings & valuation, MGTX or FULC?

Does the media refer more to MGTX or FULC?

Summary

How does Fulcrum Therapeutics compare to Aktis Oncology?

Do institutionals and insiders hold more shares of AKTS or FULC?

Does the media prefer AKTS or FULC?

Do analysts prefer AKTS or FULC?

Is AKTS or FULC more profitable?

Which has preferable valuation & earnings, AKTS or FULC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FULC vs. The Competition

Fulcrum Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools